AbbVie

Single-Patient EA Policies/Criteria ABBV-400 This program is designed to provide access to ABBV-400 prior to approval by the local regulatory agency. Availability will depend on the territory eligibility. A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. Criteria: ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT05982873?term=C24-738&rank=1 Venetoclax This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on the territory eligibility. A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. Criteria: ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT03123029?term=C19-920&rank=1 Upadacitinib oral solution This program is designed to provide access to Upadacitinib oral solution prior to approval by the local regulatory agency. Availability will depend on the territory eligibility. A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. Criteria:

Mirvetuximab Soravtansine This program is designed to provide access to Mirvetuximab Soravtansine prior to approval by the local regulatory agency. Availability will depend on the territory eligibility. A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. Criteria: Elezanumab This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on the territory eligibility. A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. Criteria: ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT04278235?lead=AbbVie&intr=Elezanumab&rank=1 Available Therapies via Single-Patient EA ABBV-400 Advanced histologically or cytologically confirmed solid tumors characterized by MET amplification Elezanumab Acute spinal cord injury Venetoclax Upadacitinib oral solution Mirvetuximab Soravtansine Platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha (FRα) expression Elezanumab – Acute Spinal Cord Injury